阿片类药物处方与代偿期肝硬化患者肝性脑病风险相关
该研究基于IQVIA PharMetrics数据库纳入6451例代偿期肝硬化患者,分析阿片类药物使用与肝性脑病(HE)的关系。结果显示,短期和长期阿片类处方均与HE风险增加相关,调整后HR分别为1.44和1.83。建议肝硬化患者尽量减少阿片类使用,必要时限制短期使用。
要点
- 代偿期肝硬化患者中,短期阿片类处方与HE风险增加相关(调整HR 1.44)。
- 长期阿片类处方与HE风险增加相关(调整HR 1.83)。
- 肝硬化患者应尽量减少阿片类使用,必要时仅短期使用。
核心结论
- 在代偿期肝硬化患者中,阿片类处方与肝性脑病发生风险增加相关。
研究设计与样本
- 基于IQVIA PharMetrics数据库的全国性队列研究,纳入6451例18-64岁代偿期肝硬化患者。
- 排除肝硬化诊断前1年至诊断后6个月内发生任何失代偿事件的患者。
- 根据肝硬化诊断后6个月内阿片类连续使用时长分为短期(1-89天)和长期(90-180天)。
- 采用landmark分析和多因素Cox比例风险回归评估阿片类使用与随后一年(诊断后6-18个月)HE发生的关联。
主要发现
- 队列中23.3%的患者有短期阿片类处方,4.7%有长期阿片类处方。
- 随后一年内,长期阿片类处方者HE发生率为6.3%,短期处方者为5.0%,无阿片类处方者为3.3%。
- 与无阿片类处方相比,短期处方者HE调整HR为1.44(95% CI 1.07-1.94),长期处方者调整HR为1.83(95% CI 1.07-3.12)。
临床怎么用
- 对代偿期肝硬化患者应尽量减少阿片类药物的使用。
- 当必须使用阿片类药物时,应限制为短期使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioids are often prescribed for pain in cirrhosis and may increase the risk of hepatic encephalopathy (HE). AIM: To assess the association between opioids and HE in patients with well-compensated cirrhosis. METHODS: We used the IQVIA PharMetrics (Durham, NC) database to identify patients aged 18-64 years with cirrhosis. We excluded patients with any decompensation event from 1 year before cirrhosis diagnosis to 6 months after cirrhosis diagnosis. Over the 6 months after cirrhosis diagnosis, we determined the duration of continuous opioid use and classified use into short term (1-89 days) and chronic (90-180 days). We assessed whether patients developed HE over the subsequent year (ie 6-18 months after cirrhosis diagnosis). We used a landmark analysis and performed multivariable Cox proportional hazards regression to assess associations between opioid use and HE, adjusting for relevant confounders. RESULTS: The cohort included 6451 patients with compensated cirrhosis, of whom 23.3% and 4.7% had short-term and chronic opioid prescriptions respectively. Over the subsequent year, HE occurred in 6.3% patients with chronic opioid prescriptions, 5.0% with short-term opioid prescriptions and 3.3% with no opioid prescriptions. In the multivariable model, an increased risk of HE was observed with short-term (adjusted hazard ratio, HR 1.44, 95% CI 1.07-1.94) and chronic opioid prescriptions (adjusted HR 1.83, 95% CI 1.07-3.12) compared to no opioid prescriptions. CONCLUSION: In this national cohort of privately insured patients with cirrhosis, opioid prescriptions were associated with the risk of incident HE. Opioid use should be minimised in those with cirrhosis and, when required, limited to short duration.
引用
- Moon AM, Jiang Y, Rogal SS, et al. Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. Aliment Pharmacol Ther. 2020. PMID: 31960985. doi:10.1111/apt.15639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。